307 related articles for article (PubMed ID: 30040088)
1. The role of targeted therapy for melanoma in the immunotherapy era.
Sullivan RJ
Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
[TBL] [Abstract][Full Text] [Related]
2. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approach to treatment of melanoma.
Ashworth MT; Daud AI
Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
5. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapies for melanoma].
Leiter U; Meier F; Garbe C
Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
[TBL] [Abstract][Full Text] [Related]
7. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Advanced Melanoma in 2020 and Beyond.
Jenkins RW; Fisher DE
J Invest Dermatol; 2021 Jan; 141(1):23-31. PubMed ID: 32268150
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.
Newcomer K; Robbins KJ; Perone J; Hinojosa FL; Chen D; Jones S; Kaufman CK; Weiser R; Fields RC; Tyler DS
Curr Probl Surg; 2022 Jan; 59(1):101030. PubMed ID: 35033317
[No Abstract] [Full Text] [Related]
11. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
12. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
13. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
Silva IP; Long GV
Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
16. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
18. SEOM clinical guideline for the management of cutaneous melanoma (2020).
Majem M; Manzano JL; Marquez-Rodas I; Mujika K; Muñoz-Couselo E; Pérez-Ruiz E; de la Cruz-Merino L; Espinosa E; Gonzalez-Cao M; Berrocal A
Clin Transl Oncol; 2021 May; 23(5):948-960. PubMed ID: 33651321
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Melanoma.
Albittar AA; Alhalabi O; Glitza Oliva IC
Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
